Healthcare Services

Congenital Adrenal Hyperplasia Market Growth Expected to Reach $0.69 Billion by 2030 with 6.8% CAGR

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Congenital Adrenal Hyperplasia Market Over The Period 2026–2030?

The congenital adrenal hyperplasia market has shown significant expansion in recent years. Its value is anticipated to rise from $0.5 billion in 2025 to $0.53 billion in 2026, advancing at a compound annual growth rate (CAGR) of 7.1%. The market’s past growth was influenced by factors including restricted enzyme replacement options, a reliance on lifelong glucocorticoid therapy, insufficient awareness in developing areas, delayed diagnoses due to a lack of screening, and a dependence on hospital-based endocrinology services.

The market for congenital adrenal hyperplasia is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $0.7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this growth during the projection period include progress in precision medicine approaches, broader availability of genetic testing, rising healthcare spending, the proliferation of specialized clinics, and enhanced patient compliance due to new drug formulations. Key trends anticipated for the forecast period encompass more extensive newborn screening programs, the development of long-acting and modified-release steroid treatments, refined mineralocorticoid and androgen suppression regimens, a growing embrace of multidisciplinary care models, and a heightened emphasis on managing the disease throughout a patient’s life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21157&type=smp

What Drivers Are Expected To Influence The Congenital Adrenal Hyperplasia Market During The Forecast Period?

An anticipated increase in the demand for gene therapy is projected to fuel the expansion of the congenital adrenal hyperplasia market moving ahead. Gene therapy is defined as a medical approach involving the alteration or manipulation of an individual’s genes to address or prevent illnesses. This escalating demand for gene therapy stems from progress in genetic research and biotechnology, facilitating more accurate and specific treatments for genetic conditions, cancers, and various chronic ailments. Congenital adrenal hyperplasia (CAH), a condition resulting from gene mutations affecting adrenal hormone production, is a significant area of focus for gene therapy, presenting avenues for precise genetic interventions to rectify fundamental genetic flaws and reinstate proper hormone function. For example, in April 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, reported that out of the 1,023 gene therapies being developed for rare diseases, eight of the top 10 rare diseases were oncological. Furthermore, the second quarter of 2024 witnessed the commencement of 76 gene therapy trials, marking a 25% rise compared to the preceding quarter. Consequently, the growing demand for gene therapy is a key factor boosting the congenital adrenal hyperplasia market.

How Is The Congenital Adrenal Hyperplasia Market Divided Into Its Major Segments?

The congenital adrenal hyperplasia market covered in this report is segmented –

1) By Type: Classic Congenital Adrenal Hyperplasia, Non-Classic Congenital Adrenal Hyperplasia

2) By Treatment And Diagnosis: Diagnosis, Treatment

3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes

Subsegments:

1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia

2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia

Which Trends Are Influencing The Congenital Adrenal Hyperplasia Market?

Major companies operating in the congenital adrenal hyperplasia market are focusing on developing innovative treatments, such as CRF1 receptor antagonists, to regulate cortisol production and reduce adrenal androgen excess. A CRF1 receptor antagonist refers to a drug that blocks the corticotropin-releasing factor 1 (CRF1) receptor to regulate the body’s stress response and reduce excessive adrenal androgen production in conditions such as congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for crenessity (crinecerfont), the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years. This oral medication acts as a selective antagonist of corticotropin-releasing factor type 1 receptors, helping to control excess adrenocorticotropic hormone (ACTH) and adrenal androgens while allowing for reduced glucocorticoid doses. Approval was based on data from the CAHtalyst Phase 3 studies, which showed significant efficacy in lowering androgen levels. Crenessity is expected to be available soon, marking a significant advancement in CAH management.

Who Are The Prominent Organizations Shaping The Congenital Adrenal Hyperplasia Market?

Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.

Read the full congenital adrenal hyperplasia market report here:

https://www.thebusinessresearchcompany.com/report/congenital-adrenal-hyperplasia-global-market-report

Which Region Is Forecast To Lead The Congenital Adrenal Hyperplasia Market In Terms Of Market Size?

North America was the largest region in the congenital adrenal hyperplasia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Congenital Adrenal Hyperplasia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21157&type=smp

Browse Through More Reports Similar to the Global Congenital Adrenal Hyperplasia Market 2026, By The Business Research Company

Conjunctivitis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/conjunctivitis-treatment-global-market-report

Aspergillosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report

Alpers Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/alpers-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795